NCT02502942.
Study name | Effects of Upper Airway Muscle Training on Obstructive Sleep Apnea (OSA). |
Methods | Parallel, RCT. |
Participants |
Inclusion criteria: 18 to 79 years old (adult, older Adult); prior diagnosis of OSA with AHI higher than 10 events/hour; PAP group: subjects who have been on PAP treatment for at least 3 months, with good compliance (at least 4 hours a day and use PAP for longer than 70% of the time). Untreated group: untreated subjects with generally mild OSA as defined by AHI lower than 20 events/hour and nadir SaO2 higher than 70%. Additionally, investigators will also recruit OSA subjects of all severities who have previously tried but are not currently using PAP. Oral appliance treatment group: subjects have residual AHI higher than 10 events/hour with oral appliance therapy. Exclusion Criteria: in those with untreated sleep apnoea, severe sleepiness with current ESS higher than 18 or history of motor vehicle accident due to obstructive sleep apnoea; taking medications classified as a muscle relaxant; pregnant women; psychiatric disorder, other than mild and controlled depression, e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders; current smokers, alcohol (higher than 3 oz/day) or use of illicit drugs. More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day. Unstable cardiac disease (e.g. CHF). Pulmonary disease (apart from well‐controlled mild asthma and OSA). Systemic neuromuscular disease. Other systemic disease that affects breathing (e.g. stroke) or those with expected survival lower than 1 year. Poor oral condition, including: active periodontal disease, loose or broken teeth, lack of eight teeth in each arch, active TMJ dysfunction. Known allergy to oral appliance components. |
Interventions |
Intervention:
Comparator:
|
Outcomes |
Primary Outcome Measures:
Secondary Outcome Measures:
Measurements: 6 weeks after treatment. |
Starting date |
Study Start Date: August 2015. Actual Study Completion Date: 24 June 2019 |
Contact information | Atul Malhotra, MD. University of California, San Diego. |
Notes | Information from ClinicalTrials.gov. |